Premium
Spinal effect of the cholecystokinin‐B receptor antagonist CI‐988 on hyperalgesia, allodynia, and morphine‐induced analgesia in diabetic and mononeuropathic rats. (Laboratoire de Physiologie, Clermont‐Ferrand Cedex 1, France) Pain 2000;88:15–22.
Author(s) -
Coudoré MarieAnge,
Courteix Christine,
Fialip Joseph,
Boucher Michel,
Eschalier Alain
Publication year - 2001
Publication title -
pain practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.899
H-Index - 58
eISSN - 1533-2500
pISSN - 1530-7085
DOI - 10.1046/j.1533-2500.2001.01023-9.x
Subject(s) - medicine , morphine , hyperalgesia , nociception , antagonist , cholecystokinin , pharmacology , allodynia , receptor antagonist , cholecystokinin b receptor , opioid , anesthesia , receptor
This study examined the effect of intrathecal CI‐99, an antagonist of the CCK‐B receptors, on mechanical hyperalgesia and allodynia in normal, mononeuropathic and diabetic rats. The effect of the combination of CI‐988 and IV morphine on mechanical hyperalgesia in diabetic and mononeuropathic rats was evaluated using isobolographic analysis. Although ineffective in normal rats, CI‐988 induced antinociceptive effects in diabetic and mononeuropathic rats, suggesting an involvement of the CCKergic system in neurogenic pain conditions. The combination of CI‐988 and morphine showed a superadditive interaction in the diabetic rats only. In addition, CI‐988 exhibited a weak antiallodynic effect in mononeuropathic rats, and no antiallodynic effect in diabetic rats. These results show the CCK‐B receptor blockade‐mediated antinociceptive effects and reveal the antinociceptive action of morphine in diabetic rats after CCKergic system inhibition.